- Q1 2024 Aclaris Therapeutics Inc Earnings Call TranscriptMay 07, 2024$1.34 (+2.29%)Earnings
- Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call TranscriptNov 13, 2023
- Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Aclaris Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2023$8.4 (-6.46%)Earnings
- Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Aclaris Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Aclaris Therapeutics Inc R&D Day (Virtual) TranscriptDec 07, 2021
- Aclaris Therapeutics Inc ATI-1777 Clinical Data Call TranscriptJun 08, 2021
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJan 19, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 17, 2020
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q4 2019 Aclaris Therapeutics Inc Earnings Call TranscriptFeb 25, 2020$1.37 (-4.20%)Earnings
- Q3 2019 Aclaris Therapeutics Inc Earnings Call TranscriptNov 07, 2019$1.69 (+4.32%)Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptOct 24, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptSep 27, 2019
- Q2 2019 Aclaris Therapeutics Inc Earnings Call TranscriptAug 08, 2019$0.99 (-2.94%)Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptJul 30, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 26, 2019
- Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study TranscriptJun 17, 2019
- Q1 2019 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2019$6.57 (-1.65%)Earnings
- Q4 2018 Aclaris Therapeutics Inc Earnings Call TranscriptMar 18, 2019Earnings
Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good morning and good afternoon, everyone. And thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Boobalan Pachaiyappan. I'm H.C. Wainwright Vice President and Senior Analyst. With me today is Dr. Neal Walker, Co-Founder, Director, and CEO of Aclaris Therapeutics. Aclaris is focused on developing novel drugs for immuno-inflammatory diseases.
Neal, the floor is yours.
Thank you. And thank you for having us. I'm Dr. Neal Walker. I'm the CEO of Aclaris. I'll be walking through an overview of the company for you today. So, Aclaris is a development-stage biotechnology company focused on the kinome and the development of small molecule therapeutics for immuno-inflammatory diseases. We have three key components to the company: the people -- we have a world-class ex-Pfizer kinase leadership with decades of experience looking at the kinome; we also have the KINect platform, which
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)